高级检索
当前位置: 首页 > 详情页

Expression of Leptin and Sirtuin-1 is associated with poor prognosis in patients with osteosarcoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Key Laboratory of Physiology and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, 20 Nanerhuan East Road, Shijiazhuang 050024, Hebei, China [2]Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang 050011, Hebei, China
出处:
ISSN:

关键词: Leptin Sirtuin-1 Osteosarcoma Prognostic indicator

摘要:
Sirtuin-1 (SIRT1) is a downstream target of Leptin, and its inhibition promotes p53-mediated apoptosis. This study aimed to evaluate the expression and prognostic significance of Leptin and SIRT1 in osteosarcoma. Leptin and SIRT1 levels in osteosarcoma samples from 89 patients were evaluated by immunohistochemical staining. The correlations between Leptin and SIRT1 expression with clinical parameters were analyzed by Spearman's test and Pearson's chi-squared test. Prognostic factors were identified by Univariate and multivariate Cox regression analysis. We found that Leptin and SIRT1 expression was low in 23.6% and 20.2%; moderate in 25.8% and 24.7%; and high in 50.5% and 55.1% of patients with osteosarcoma, respectively. Both Leptin and SIRT1 expression were significantly associated with the Enneking stage, distant metastasis and neo-adjuvant chemotherapy. Leptin expression and SIRT1 expression were significantly correlated and they were significantly associated with shorter overall survival. Among osteosarcoma patients who received neo-adjuvant chemotherapy, both Leptin and SIRT1 expression were significantly associated with overall survival of osteosarcoma patients in univariate analysis, but only SIRT1 expression was significantly associated with overall survival of osteosarcoma patients in multivariate analysis. In conclusion, Leptin and SIRT1 expressions are significantly associated with shorter overall survival of osteosarcoma patients, and SIRT1 expression is a significant independent prognostic indicator in patients with osteosarcoma. (C) 2016 Elsevier GmbH. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 病理学
JCR分区:
出版当年[2016]版:
Q3 PATHOLOGY
最新[2024]版:
Q2 PATHOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Key Laboratory of Physiology and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, 20 Nanerhuan East Road, Shijiazhuang 050024, Hebei, China [2]Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang 050011, Hebei, China
通讯作者:
通讯机构: [1]Key Laboratory of Physiology and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, 20 Nanerhuan East Road, Shijiazhuang 050024, Hebei, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号